down arrow

Genelux Corp.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US36870H1032
USD
4.20
0.01 (0.24%)

Dec 19

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

4.104.30

52 Week

1.998.54
Valuation
Technical
Day's Volume

CASH

173.34 k

Shareholding (Mar 2025)

FII

1.65%

Held by 19 FIIs

DII

89.71%

Held by 10 DIIs

Promoter

0.00%

How big is Genelux Corp.?

22-Jun-2025

As of Jun 18, Genelux Corp. has a market capitalization of 115.27 million, with net sales of 0.00 million and a net profit of -29.52 million over the latest four quarters. Shareholder's funds are 26.27 million, and total assets are 34.72 million.

As of Jun 18, Genelux Corp. has a market capitalization of 115.27 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 0.00 million, while the sum of Net Profit for the same period is -29.52 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 26.27 million and Total Assets at 34.72 million.

Read More

What does Genelux Corp. do?

22-Jun-2025

Genelux Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $7 million and a market cap of $115.27 million. It has no dividend yield and negative key financial metrics, including a return on equity of -100.12%.

Overview:<BR>Genelux Corp. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Net Profit: -7 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 115.27 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -1.16<BR>Return on Equity: -100.12%<BR>Price to Book: 3.86<BR><BR>Contact Details:<BR>Details: No Company Details Available<BR>Registrar Address: Not available.

Read More

Is Genelux Corp. overvalued or undervalued?

25-Jun-2025

As of November 14, 2023, Genelux Corp. is considered overvalued and does not qualify for investment due to negative financial metrics, including a P/E ratio of -3.8576, despite a strong one-year stock return of 34.47%.

As of 14 November 2023, Genelux Corp. has moved from a grade of risky to does not qualify. The company is currently considered overvalued, given its negative financial metrics and lack of profitability. Key ratios include a Price to Book Value of 3.27, an EV to EBIT of -2.00, and an EV to EBITDA of -2.06, all indicating significant financial distress.<BR><BR>In comparison to its peers, Genelux Corp. has a P/E ratio of -3.8576, while Viridian Therapeutics, Inc. also does not qualify with a P/E of -4.1277. Notably, Travere Therapeutics, Inc. is rated risky with a P/E of -5.5910, while PetIQ, Inc. stands out as fairly valued with a P/E of 27.1022. Despite a strong one-year stock return of 34.47% compared to the S&P 500's 10.26%, the fundamental metrics suggest that Genelux Corp. is not a sound investment at its current valuation.

Read More

Is Genelux Corp. technically bullish or bearish?

20-Sep-2025

As of September 4, 2025, Genelux Corp. shows a bullish technical trend supported by positive MACD and Bollinger Bands, despite a bearish KST, with a year-to-date return of 69.92% significantly outperforming the S&P 500's 12.22%.

As of 4 September 2025, the technical trend for Genelux Corp. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands indicate a bullish stance. Daily moving averages also support a bullish outlook. However, the KST is bearish on a weekly basis, and the Dow Theory shows a mildly bullish trend in both weekly and monthly assessments. The stock has significantly outperformed the S&P 500 over multiple periods, with a year-to-date return of 69.92% compared to the S&P 500's 12.22%. Overall, the current technical stance is bullish with moderate strength.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 136 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.16

stock-summary
Return on Equity

-128.72%

stock-summary
Price to Book

5.69

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-7 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.96%
0%
0.96%
6 Months
43.84%
0%
43.84%
1 Year
91.78%
0%
91.78%
2 Years
-69.14%
0%
-69.14%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Genelux Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-97.00%
EBIT Growth (5y)
-392.09%
EBIT to Interest (avg)
-19.10
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.16
Sales to Capital Employed (avg)
0.32
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
30.13%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.27
EV to EBIT
-2.00
EV to EBITDA
-2.06
EV to Capital Employed
-12.80
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-100.12%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 14 Schemes (8.64%)

Foreign Institutions

Held by 19 Foreign Institutions (1.65%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -13.64% vs -13.79% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.60",
          "val2": "-6.70",
          "chgp": "-13.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.50",
          "val2": "-6.60",
          "chgp": "-13.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs -98.20% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -5.65% vs -444.23% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-30.80",
          "val2": "-23.10",
          "chgp": "-33.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "4.00",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.40",
          "val2": "-0.40",
          "chgp": "200.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-29.90",
          "val2": "-28.30",
          "chgp": "-5.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-3,962,000.00%",
          "val2": "-142,147.10%",
          "chgp": "-3,81,985.29%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-7.60
-6.70
-13.43%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-7.50
-6.60
-13.64%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -13.64% vs -13.79% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.20
-100.00%
Operating Profit (PBDIT) excl Other Income
-30.80
-23.10
-33.33%
Interest
0.00
4.00
-100.00%
Exceptional Items
0.40
-0.40
200.00%
Consolidate Net Profit
-29.90
-28.30
-5.65%
Operating Profit Margin (Excl OI)
-3,962,000.00%
-142,147.10%
-3,81,985.29%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs -98.20% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -5.65% vs -444.23% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Genelux Corp. stock-summary
stock-summary
Genelux Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."